REN and hydrops fetalis: Renin-angiotensin system inhibitors (RASI) and β-blockers have proven prognostic benefit and are recommended by guidelines in all patients with HF and reduced ejection fraction (HFrEF), unless contraindicated or not tolerated [2, 3].